Key Highlights
- Philip Morris International (NYSE: PM) will report Q2 FY2026 earnings on July 22, 2026.
- Wall Street expects adjusted EPS of $2.03 on $10.60 billion in revenue.
- Smoke-free products now contribute approximately 43% of total net revenue.
- Investors will closely monitor IQOS shipments, ZYN pouch demand, and regulatory developments.
- Management reaffirmed full-year adjusted EPS guidance of $8.36 to $8.51.
Philip Morris Looks to Extend Its Winning Streak
Philip Morris International (NYSE: PM) will report second-quarter fiscal 2026 results before the market opens on July 22, with investors looking for another strong quarter from one of the consumer staples sector's best-performing companies.
Wall Street expects the tobacco giant to post adjusted earnings per share of $2.03 on revenue of approximately $10.60 billion. Expectations remain elevated after Philip Morris delivered another solid first quarter, reporting adjusted EPS of $1.96, comfortably ahead of consensus estimates of $1.83, while revenue increased 9.1% year over year to $10.15 billion.
The company has also built a reputation for consistent execution, beating analyst EPS estimates in six of the past seven quarters. Management's own second-quarter earnings guidance of $2.02 to $2.07 per share suggests confidence that operational momentum has continued through the first half of the year.
Smoke-Free Products Remain the Primary Growth Engine
The biggest focus for investors will once again be Philip Morris' smoke-free business, which has transformed the company's long-term growth profile.
Smoke-free products now generate approximately 43% of total net revenues, underscoring the company's successful transition beyond traditional combustible cigarettes.
Within that portfolio, IQOS heated tobacco products remain the company's flagship platform. Investors will closely examine shipment volumes, market share gains, and user adoption across key international markets to assess whether IQOS continues to drive sustainable revenue growth.
Another area attracting considerable attention is ZYN nicotine pouches, particularly following the U.S. launch of ZYN ULTRA in early June. Demand trends will provide an early indication of consumer acceptance and whether the premium product can accelerate growth in the rapidly expanding oral nicotine category.
Pricing Power and Organic Growth Will Be Closely Watched
While smoke-free products remain the primary growth driver, Philip Morris continues to benefit from strong pricing power across its combustible cigarette portfolio.
Analysts will look for evidence that the company can continue offsetting declining cigarette volumes through strategic price increases, particularly in developed markets where premium tobacco brands remain resilient.
Organic revenue growth will also be an important measure of underlying business strength, helping investors distinguish operational performance from currency fluctuations and acquisition-related impacts.
Regulatory Updates Could Influence Investor Sentiment
Beyond quarterly financial results, management's outlook on regulation could significantly influence the stock's post-earnings performance.
One of the most anticipated updates involves the expected U.S. Food and Drug Administration (FDA) authorization for IQOS. Management previously indicated that regulatory approval may arrive sooner than originally anticipated, potentially opening a significant new growth opportunity in the U.S. market.
Investors will also monitor developments surrounding potential European flavor restrictions and evolving regulations governing nicotine pouches, both of which could affect future sales growth.
Given Philip Morris' presence in more than 175 international markets, foreign exchange movements remain another important variable that could influence reported earnings and guidance.
Outlook
Philip Morris enters its second-quarter earnings release with strong operational momentum, a growing smoke-free business, and a consistent history of outperforming Wall Street expectations. Continued growth in IQOS and ZYN, combined with resilient pricing across its traditional tobacco portfolio, should remain key drivers of revenue and earnings.
However, with the stock trading near record highs, investor expectations are equally elevated. Any slowdown in smoke-free product growth, cautious guidance, or unfavorable regulatory developments could weigh on sentiment despite another solid quarter.
Q. When will Philip Morris report Q2 FY2026 earnings?
A. Philip Morris International is scheduled to release Q2 FY2026 earnings on July 22, 2026.
What are Wall Street's expectations?
Analysts expect adjusted EPS of $2.03 on revenue of approximately $10.60 billion.
What percentage of revenue comes from smoke-free products?
Smoke-free products now account for approximately 43% of Philip Morris' total net revenue.
Why are IQOS and ZYN important?
IQOS heated tobacco devices and ZYN nicotine pouches are the company's fastest-growing product categories and central to its long-term smoke-free strategy.
What are the biggest risks heading into earnings?
Key risks include regulatory changes, FDA approval timing for IQOS in the U.S., nicotine pouch regulations, currency fluctuations, and the sustainability of organic revenue growth.
This article is for informational purposes only and should not be considered investment advice.






Please wait processing your request...